277 related articles for article (PubMed ID: 27462009)
1. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
Binkley N; Bone H; Gilligan JP; Krause DS
Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
[TBL] [Abstract][Full Text] [Related]
3. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
Adami S; Baroni MC; Broggini M; Carratelli L; Caruso I; Gnessi L; Laurenzi M; Lombardi A; Norbiato G; Ortolani S
Osteoporos Int; 1993; 3 Suppl 3():S21-7. PubMed ID: 8298199
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
[TBL] [Abstract][Full Text] [Related]
7. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.
Rico H; Revilla M; Hernández ER; Villa LF; Alvarez de Buergo M
Calcif Tissue Int; 1995 Mar; 56(3):181-5. PubMed ID: 7750020
[TBL] [Abstract][Full Text] [Related]
8. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Bone HG; Dempster DW; Eisman JA; Greenspan SL; McClung MR; Nakamura T; Papapoulos S; Shih WJ; Rybak-Feiglin A; Santora AC; Verbruggen N; Leung AT; Lombardi A
Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
[TBL] [Abstract][Full Text] [Related]
9. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
Overgaard K; Hansen MA; Jensen SB; Christiansen C
BMJ; 1992 Sep; 305(6853):556-61. PubMed ID: 1393035
[TBL] [Abstract][Full Text] [Related]
10. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
Kollerup G; Hermann AP; Brixen K; Lindblad BE; Mosekilde L; Sørensen OH
Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
[TBL] [Abstract][Full Text] [Related]
11. The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.
Moore AE; Dulnoan D; Voong K; Ayis S; Mangelis A; Gorska R; Harrington DJ; Tang JCY; Fraser WD; Hampson G
Arch Osteoporos; 2023 Jun; 18(1):83. PubMed ID: 37338608
[TBL] [Abstract][Full Text] [Related]
12. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
[TBL] [Abstract][Full Text] [Related]
13. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K; Lindsay R; Christiansen C
Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
[TBL] [Abstract][Full Text] [Related]
14. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
[TBL] [Abstract][Full Text] [Related]
15. Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine.
Szücs J; Horváth C; Kollin E; Szathmári M; Holló I
Calcif Tissue Int; 1992 Jan; 50(1):7-10. PubMed ID: 1739873
[TBL] [Abstract][Full Text] [Related]
16. Postmenopausal osteoporosis: patient choices and outcomes.
Cosman F; Nieves J; Walliser J; Lindsay R
Maturitas; 1995 Sep; 22(2):137-43. PubMed ID: 8538482
[TBL] [Abstract][Full Text] [Related]
17. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study.
Lyritis GP; Tsakalakos N; Magiasis B; Karachalios T; Yiatzides A; Tsekoura M
Calcif Tissue Int; 1991 Dec; 49(6):369-72. PubMed ID: 1818759
[TBL] [Abstract][Full Text] [Related]
18. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study.
Ljunghall S; Gärdsell P; Johnell O; Larsson K; Lindh E; Obrant K; Sernbo I
Calcif Tissue Int; 1991 Jul; 49(1):17-9. PubMed ID: 1893291
[TBL] [Abstract][Full Text] [Related]
19. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
[TBL] [Abstract][Full Text] [Related]
20. Nasal calcitonin for treatment of established osteoporosis.
Overgaard K; Riis BJ; Christiansen C; Pødenphant J; Johansen JS
Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
